- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00535431
Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics
September 22, 2007 updated by: Aerovance, Inc.
A Study To Investigate The Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatic Subjects
This is a single centre, double-blind, randomised, parallel group, repeated dose asthmatic subjects.
Subjects will receive AER 001 (60 mgs) or placebo twice daily for 28 days.
Before and after treatment subjects will be experimentally challenged with inhaled allergen to induce decreases in lung function.
The primary outcome is late phase response to allergen as measured by the average percent change in FEV1 from 4-10 hours following allergen.
Because AER 001 is a Th2 anti-inflammatory, it is hypothesized that AER 001 treatment will inhibit the late phase response to allergen challenge.
Study Overview
Detailed Description
Objectives:
Primary Objective To investigate the effects of AER 001 on the late asthmatic response in mild to moderate asthmatics
Secondary Objectives
- To examine the effects of AER 001 on antigen induced airway hyperactivity to adenosine monophosphate and blood levels of circulating IgE.
- To characterise the pharmacokinetics of nebulised AER 001.
Exploratory Objectives
- To examine the effects of AER 001 on circulating sIL-13Rα2 and IFNgamma.
- To examine the results of single nucleotide polymorphism (SNP) analysis of IL-4, IL-13, IL-4Rα and IL-13R α to determine if there is any correlation between AER 001 response and genotype
- To examine levels of anti-AER 001 following administration of AER 001
Methodology:
- Single centre, double-blind, randomised, parallel group, repeated dose study in male and female asthmatic subjects.
- A sufficient number of subjects (at least 30 subjects) will be recruited to ensure that at least 26 completed sets of data will be obtained.
- Subjects will be randomised to receive either AER 001 60 mg / matched volume Placebo in a ratio of 1 active : 1 placebo ( block size of 6).
- Treatments will be administered by nebulization from a PARI LC Plus nebulizer
- Subjects are to receive b.i.d. administration of AER 001 / placebo for 27 days. A morning dose will be given on Day 28, (24 hours after Day 27 am-dose).
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, SE1 1YR
- Guy's Drug Research Unit, Quintiles, Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
• Adult males and females > 18 years.
- Subjects who if female, are not currently pregnant or breast feeding and are using medically acceptable methods of contraception.
- Subjects who have a pre study medical history, physical examination, 12 Lead ECG acceptable to the investigator.
- Subjects who have clinical laboratory tests within the reference ranges or clinically acceptable to the investigator.
- Subjects who are negative for HbsAg, hepatitis C antibody and HIV II and I test at screening.
- Subjects who are negative for drugs of abuse and alcohol tests at screening and admission.
- Positive response on screening to a skin prick test.
- Adenosine monophosphate PC20 on screening of ≥ 0.04 mg/ml
- Subjects, who on the Allergen challenge, have a PC20 on allergen and exhibit a late phase response following the allergen challenge.
- Subjects who have a FEV1 > 70% of predicted.
- Subjects who have not received steroid treatment in the prior month.
- Subjects who are non-smokers for at least 3 months prior to screening.
- Have a < 10 pack year history.
- Satisfies the Global Initiative in Asthma (GINA, 2002) definition of asthma or have been on treatment for asthma.
- Subjects with stable, adequately treated medical conditions may be enrolled provided the Principal Investigator does not consider their study participation to place them at increased risk of adverse events. Subjects should continue their concomitant treatments without change during the study.
- Subjects who are able and willing to give written informed consent.
Exclusion Criteria:
• Subjects who do not conform to the above inclusion criteria.
- Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders which would preclude antigen challenge.
- Subjects who have a clinically relevant surgical history which would preclude antigen challenge.
- Subjects who have a clinically relevant family history which would preclude antigen challenge.
- Subjects who have a history of relevant drug hypersensitivity.
- Subjects who have a history of alcoholism.
- Subjects who have a history of drug abuse.
- Subjects who consume more than 28 units (male)/ 21 units (female) of alcohol a week.
(unit = 1 glass of wine = 1 measure of spirits = ½ pint of beer)
- Subjects who have acute gastrointestinal symptoms at the time of screening and/or admission (e.g. nausea, vomiting, diarrhoea, heartburn)
- Subjects who have an acute respiratory infection such as influenza at the time of screening and/or admission.
- Female subjects who are not using an acceptable method of contraception.
- Subjects who have used any investigational drug and /or participated in any clinical trial within 3 months of their first dosing.
- Subjects using medication, which in the opinion of the Investigator will affect the outcome of the study.
- Subjects who have donated and/or received any blood or blood products within the previous 3 months prior to first dosing (to review on a case by case basis).
- Subjects who cannot communicate reliably with the investigator.
- Subjects who are unlikely to co-operate with the requirements of the study.
- Subjects who have previously taken AER 001
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
AER 001
|
60 mg (in nebuliser), twice daily for 28 days
Other Names:
|
Placebo Comparator: P
sterile saline
|
Sterile saline nebulised, twice daily for 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To investigate the effects of AER 001 on the late asthmatic response in mild to moderate asthmatics as measured by average percent fall in FEV1 from 4-10 hours post allergen challenge (i.e. the late phase response)after 28 days of treatment
Time Frame: pre- vs. post 28 days of treatment
|
pre- vs. post 28 days of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary Objectives • To examine the effects of AER 001 on antigen induced airway hyperactivity to adenosine monophosphate and blood levels of circulating IgE. • To characterise the pharmacokinetics of nebulised AER 001.
Time Frame: pre- vs. post 28 days of treatment
|
pre- vs. post 28 days of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Darren Wilbraham, MD, Guy's Drug Research Unit, Quintiles Ltd.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2005
Study Completion (Actual)
October 1, 2006
Study Registration Dates
First Submitted
September 22, 2007
First Submitted That Met QC Criteria
September 22, 2007
First Posted (Estimate)
September 26, 2007
Study Record Updates
Last Update Posted (Estimate)
September 26, 2007
Last Update Submitted That Met QC Criteria
September 22, 2007
Last Verified
September 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- QGUY/2005/AER 001/-03
- EUDRACT 2005-004829-26
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Asthma
-
University of ZurichUniversity of AarhusActive, not recruitingAllergic Rhinitis Due to Grass Pollen | Allergic Rhinitis | Rhinitis, Allergic, Seasonal | Allergic Asthma | Rhinitis; Allergic, With AsthmaSwitzerland
-
Children's Mercy Hospital Kansas CityCompletedAsthma | Allergic Asthma | Non-allergic AsthmaUnited States
-
ALK-Abelló A/SCompletedAllergic Rhinitis Due to House Dust Mite | Allergic Asthma Due to Dermatophagoides Farinae | Allergic Asthma Due to Dermatophagoides PteronyssinusPoland, United Kingdom, Spain, United States, Russian Federation, Hungary, France, Bulgaria, Germany
-
ALK-Abelló A/SITEC ServicesCompletedAllergic Rhinitis Due to House Dust Mite | Allergic Asthma Due to Dermatophagoides Farinae | Allergic Asthma Due to Dermatophagoides PteronyssinusFrance
-
The Cleveland ClinicEnrolling by invitation
-
Leti Pharma GmbHCompletedAllergic Asthma | Allergic RhinoconjunctivitisGermany
-
Inmunotek S.L.BioClever 2005 S.L.; NTS hub S.LNot yet recruitingPerennial Allergic Rhinitis | Allergic Asthma | Allergic Rhinoconjunctivitis | House Dust Mite AllergySpain
-
University Hospital, AkershusOslo University Hospital; ImmunoPharma ASRecruitingAllergic Asthma | Allergic Rhinoconjunctivitis | Immune ToleranceNorway
-
Johann Wolfgang Goethe University HospitalCompleted
-
University of North Carolina, Chapel HillNational Institutes of Health (NIH)TerminatedMild Allergic Rhinitis | Mild Allergic Rhinitis With Mild AsthmaUnited States
Clinical Trials on AER 001
-
Aerovance, Inc.CompletedAtopic EczemaUnited Kingdom
-
Aerovance, Inc.Quintiles, Inc.CompletedAllergic AsthmaUnited Kingdom
-
Aerovance, Inc.Completed
-
GI View Ltd.CompletedRectal Cancer | Colon CancerIsrael
-
Centre for Neuro SkillsUniversity of PittsburghEnrolling by invitation
-
Aeromics, Inc.CovanceCompleted
-
Centre for Neuro SkillsUnknown
-
Aerami TherapeuticsCompletedPulmonary Arterial HypertensionAustralia
-
Aerovance, Inc.CompletedAsthmaUnited States, United Kingdom, Hungary, Poland